MedPath

The effect of Terazosin and Tolterodine in the treatment of double J stent-related urinary symptoms

Phase 3
Conditions
lower urinary tract symptoms, ureteral stone.
Urinary calculus, unspecified
N20.9
Registration Number
IRCT20160924029935N2
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

patients with ureteral stones undergoing unilateral transurethral lithotripsy

Exclusion Criteria

History of major urinary surgery
Benign prostate hyperplasia under medical therapy
Overactive bladder
Drug sensitivity

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
reteral stent urinary symptoms. Timepoint: 2 weeks after intervention. Method of measurement: Ureteral Stent Symptoms Questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath